Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. Securities Purchase Agreement On December 17, 2025, Kalaris Therapeutics, Inc., a Delaware corporation (the “Company
Unregistered Sales of Equity Securities. The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. Based in part upo
Other Events. Press Release On December 17, 2025, the Company issued a press release announcing the Private Placement. A copy of the press release is attached a
Financial Statements and Exhibits. (d) Exhibits 4.1 Form of Pre-Funded Warrant 10.1 Securities Purchase Agreement, dated December 17, 2025, by and among the Com